After a month of announcing promises from some of the country’s largest companies to help President Trump announce a national emergency and enhance test capabilities in the United States, most areas have yet to receive the required testing and Lack of access to equipment.
When the president stepped up to the podium at Rose Garden in March, it was expected to be surrounded by the country’s largest pharmacies and retailers, including Target, Walmart, CVS and Walgreens. The nation was soon to witness an explosion in the testing facilities that could provide. In order to manage the outbreak across the country, such population-scale testing is essential.
President Trump also said at the time that a team of 1,700 engineers from Google was developing a tragedy tool to assess whether anyone should pass code 19 tests and send them to such sites. Wherever these tests can be performed.
Reality has fallen far short of those expectations. Google was not responsible for the development of the trash tool that the president described. The development was attempted by another parent company, Google’s parent company, Alphabet, and by the end of March it had completed 3,700 tests. The company managed to establish four testing sites in California in two weeks.
Attempts to make screening available in pharmacies nationwide are also under way. Last week, Walgreens said it was expanding its testing capabilities to 15 locations in seven states. It’s from a site at the end of March. Each site can test 3,000 people daily, the company said. And CVS is spreading from one site in Massachusetts to four sites, with two in Massachusetts, and one in Rhode Island and Georgia. Its sites have the capacity to test 1,000 people a day.
Meanwhile, Target has not opened a single facility.
“At this time, federal, state and local officials continue to lead the planning of additional testing sites,” a target spokesman told National Public Radio. When we are ready for the activity, we are committed to offering our parking spots and supporting their efforts.
Both CVS and Walgreens are using Abbott’s new ID-9Code-19 test, but both companies are not testing the scale that medical professionals say is about to reopen the US economy. It is appropriate to proceed with (some of which were pundits. Advocate for May as soon as possible).
In fact, the pace of scrutiny is lagging behind in both public and private facilities across the country, partly because only people with severe COVID-19 symptoms are experiencing the disease.
As Vox reported over the weekend, the United States tested the South Korean rate at 74 percent. Whereas testing and tracing has largely prevented the outbreak from becoming very serious – and not even reaching the test levels of other severely affected countries. Canada, Germany, and Italy.
Part of the problem is the lack of equipment needed to perform the required scale tests. The United States is rushing to find important personal protective equipment for health workers, most of which is at risk in Quad 19, but they are also fleeing the equipment they need to examine patients.
Just today, the Los Angeles Times reported that the scrutiny needed in New York may be over. “It is still a great shortage environment,” the Times quoted Mayor Bill de Blasio as saying. “I spoke with the president and other key members of the administration … This is an important requirement.”
Earlier today, Ford announced a partnership with Thermo Fisher, which aims to reduce the shortage of test kits and personal protective equipment, but it is far from the only company to start working on this particular shortcoming. Last month, privately held by 3D printing technology such as Carbon, Mark Forged, and Farm Labs, they announced efforts to develop both personal protective equipment and required test swabs to test COVID-19.
But even with more flags, there may not be enough scope for testing to meet the growing demand.
Already, Quest Diagnostics, one of the private testing firms that performs COVID-19 tests, has two days to back up cases, according to its latest statement on testing.
According to a NPR report, the lobbying group representing them in Quest, LabCorp and Washington has contacted the White House to increase their ability to examine those who may be affected.
In early March, the companies contacted the government with three requests: funds to build new testing facilities. Standards to ensure that testing is done correctly and provided to the right people. And assistance in obtaining the equipment needed to carry out the test. To date, companies have not received that guidance or assistance, according to NPR.
Testing remains the lynchpin for any successful attempt to successfully control the spread of COVID-19, according to a Duke University report in which former FDA commissioner for multibillion-dollar venture capital New Enterprise Associates And partner Scott Gottlieb’s co-author.
“The ability to perform rapid diagnostic tests for everyone with COVID-19 symptoms and those at risk or at high risk of contracting or transmitting the virus (health workers, in community settings) According to the study, the first step in any successful control plan, especially in vulnerable populations, is to infect population specimens for early detection of small outbreaks.
Even Google and Apple’s efforts to develop contact tracing technology need the help of more robust testing capabilities.
So far, the US president has not met the testing goals set in Baghdad. “It’s going pretty fast,” he said of the new test approval process. “It’s moving pretty fast – which will bring 1.4 million on board next week and 5 million tests a month. I doubt we’ll need anywhere near that.”
When the President addressed his Rose Garden in March this Friday, 2,006 people had a positive experience of the disease and 42 died.
To date, the United States has performed 2.935 million tests, 576,774 positive cases, 2,358,232 negative cases, and 17,159 pending cases. And 23,369 people have died from the disease in the United States.